Infection

Global Anti-aging Market (2021 to 2026) - Growth, Trends, COVID-19 Impact, and Forecasts - ResearchAndMarkets.com

Wednesday, April 14, 2021 - 7:40pm

Also, rapid weight loss or gain and pregnancy are the most common reasons leading to stretch marks.

Key Points: 
  • Also, rapid weight loss or gain and pregnancy are the most common reasons leading to stretch marks.
  • For instance, in January 2018, New York-based pregnancy brand Hatch launched a belly mask that provides hydration and helps minimize stretch marks.
  • However, research on utilizing few anti-aging drugs in the treatment of COVID-19 infection is being carried out by few researchers.
  • Thus, in view of the aforementioned factors, the studied market is expected to grow significantly in North America.\n"

 FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications

Monday, April 12, 2021 - 6:20pm

After Xolair therapy has been initiated and safely established in a healthcare setting, a healthcare provider may determine whether self-injection with Xolair prefilled syringe by the patient or a caregiver is appropriate.

Key Points: 
  • After Xolair therapy has been initiated and safely established in a healthcare setting, a healthcare provider may determine whether self-injection with Xolair prefilled syringe by the patient or a caregiver is appropriate.
  • For children 12 years of age and older, XOLAIR prefilled syringe may be self-injected under adult supervision.
  • Some people who are at a high risk for parasite (worm) infections, get a parasite infection after receiving XOLAIR.
  • Patients should call their doctor for medical advice about side effects.\nPatients may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch .

The Only Proven, Effective Bovine Anaplasmosis Vaccine Available for a Global Cattle Market: 'University Products LLC' Highlights Two Decades of Success with Proprietary Formula - Also Offers Hope in Global Fight Against Bovine Babesiosis

Wednesday, April 14, 2021 - 1:38pm

Although it does not prevent infection, it significantly reduces clinical signs and helps prevent cattle death.

Key Points: 
  • Although it does not prevent infection, it significantly reduces clinical signs and helps prevent cattle death.
  • News of our vaccine has quietly circulated via word-of-mouth and through internal press releases.
  • This is a cost-effective answer to the U.S. anaplasmosis problem, and we know our product works.
  • "\nFor more information on the ongoing study, or to read Dr. Thompson\'s full analysis of anaplasmosis treatment, contact Dr. Luther directly by email at docndoc@aol.com .\n'

Companion Animal Pharmaceuticals Market worth $18.5 billion by 2026 - Exclusive Report by MarketsandMarkets™

Monday, April 12, 2021 - 1:30pm

b'The growth in this market is majorly driven by the growth in companion animal ownership, rising prevalence of zoonotic diseases, rising demand for pet insurance with the growing animal health expenditure, and initiatives by various government agencies and animal associations.

Key Points: 
  • b'The growth in this market is majorly driven by the growth in companion animal ownership, rising prevalence of zoonotic diseases, rising demand for pet insurance with the growing animal health expenditure, and initiatives by various government agencies and animal associations.
  • The infectious diseases segment accounted for the largest share of the market.
  • The veterinary hospitals segment holds the largest share in the companion animal pharmaceuticals market due to the higher adoption of animal parasiticides and antibiotics in hospital settings, increasing incidence of infectious diseases, growing number of veterinary hospitals, growing ownership of companion animals, increasing veterinary expenditure, and growing awareness about animal health in developing countries.\nThe companion animal pharmaceuticals market in the APAC region is expected to register the highest CAGR during the forecast period.
  • Ltd. (India).\nAnimal Antibiotics and Antimicrobials Market by Product (Tetracycline, Penicillin, Sulfonamide, Macrolide, Cephalosporin, Lincosamide), Mode of Delivery (Premixes, Oral Solution, Injection), Animal (Food producing & Companion) - Global Forecast to 2026\n'

Companion Animal Pharmaceuticals Market worth $18.5 billion by 2026 - Exclusive Report by MarketsandMarkets™

Monday, April 12, 2021 - 1:30pm

b'The growth in this market is majorly driven by the growth in companion animal ownership, rising prevalence of zoonotic diseases, rising demand for pet insurance with the growing animal health expenditure, and initiatives by various government agencies and animal associations.

Key Points: 
  • b'The growth in this market is majorly driven by the growth in companion animal ownership, rising prevalence of zoonotic diseases, rising demand for pet insurance with the growing animal health expenditure, and initiatives by various government agencies and animal associations.
  • The infectious diseases segment accounted for the largest share of the market.
  • The veterinary hospitals segment holds the largest share in the companion animal pharmaceuticals market due to the higher adoption of animal parasiticides and antibiotics in hospital settings, increasing incidence of infectious diseases, growing number of veterinary hospitals, growing ownership of companion animals, increasing veterinary expenditure, and growing awareness about animal health in developing countries.\nThe companion animal pharmaceuticals market in the APAC region is expected to register the highest CAGR during the forecast period.
  • Ltd. (India).\nAnimal Antibiotics and Antimicrobials Market by Product (Tetracycline, Penicillin, Sulfonamide, Macrolide, Cephalosporin, Lincosamide), Mode of Delivery (Premixes, Oral Solution, Injection), Animal (Food producing & Companion) - Global Forecast to 2026\n'

IDbyDNA Shares Insights on Role of Metagenomics for Tracking COVID-19 on New Illumina Podcast

Friday, April 9, 2021 - 2:00pm

On this podcast, IDbyDNA Chief Medical Officer and Co-Founder Dr. Robert Schlaberg and Head of Medical Affairs Dr. Lauge Farnaes address the role of sequencing to identify emerging pathogens, such as SARS-CoV-2, as well as the future of clinical metagenomics.

Key Points: 
  • On this podcast, IDbyDNA Chief Medical Officer and Co-Founder Dr. Robert Schlaberg and Head of Medical Affairs Dr. Lauge Farnaes address the role of sequencing to identify emerging pathogens, such as SARS-CoV-2, as well as the future of clinical metagenomics.
  • "Medicine is on the cusp of the most dramatic change in infectious disease work since the discovery of antibiotics," said Dr. Farnaes.
  • Explify data analytics enable laboratories to detect and profile tens of thousands of microorganisms from any specimen in a scalable, intuitive way at genomic-level resolution.
  • Our industry-leading expertise in microbial genomics delivers comprehensive, actionable infectious disease testing and pathogen surveillance.

Claritas to Expand R-107 Program to Include Treatment of Sepsis, the Leading Cause of Death in COVID-19 Patients

Thursday, April 8, 2021 - 1:15pm

Claritas is currently developing R-107 for the treatment of viral infections, including vaccine-resistant COVID-19.

Key Points: 
  • Claritas is currently developing R-107 for the treatment of viral infections, including vaccine-resistant COVID-19.
  • A control group consisted of 13 sheep that were treated with an intramuscular injection of saline.
  • Most COVID-19 infections cause mild to moderate illness with respiratory and flu-like symptoms, including fever, chills, cough and sore throat.
  • Claritas Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing therapies for patients with significant unmet medical needs.

Hologic to Acquire Mobidiag, Innovator in Near-Patient, Acute Care Diagnostic Testing, for Approximately $795 Million

Thursday, April 8, 2021 - 1:00pm

This includes a cash payment of approximately $714 million (600 million) for Mobidiags equity, and net debt of approximately $81 million.

Key Points: 
  • This includes a cash payment of approximately $714 million (600 million) for Mobidiags equity, and net debt of approximately $81 million.
  • Mobidiag develops and markets PCR (polymerase chain reaction)-based tests for acute care conditions such as gastrointestinal and respiratory infections, antimicrobial resistance management, and healthcare associated infections.
  • The Amplidiag and Novodiag platforms are automated instruments that deliver rapid turnaround times ranging from 50 minutes to two hours.
  • Mobidiag generated approximately $42 million (35 million) of revenue in calendar 2020.

Cidara Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

Wednesday, April 7, 2021 - 1:00pm

Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections.

Key Points: 
  • Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections.
  • The Companys portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases from Cidaras proprietary Cloudbreak antiviral platform.
  • Cidara is headquartered in San Diego, California.
  • For more information, please visit www.cidara.com .

Iterum Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

Tuesday, April 6, 2021 - 1:30pm

Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world.

Key Points: 
  • Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world.
  • Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation and IV formulation.
  • Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.
  • Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.